The short version of lyophilisation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
== Other animals == The epididymis is present in male reptiles, birds, mammals, and cartilaginous fish. The caput epididymidis is fused to the testis in eutherian mammals, but not in marsupials. In reptiles, there is an additional canal between the testis and the head of the epididymis, which receives the various efferent ducts. This is, however, absent in all birds and mammals.
=== Noncoding RNA controls epigenetic phenomena === In addition to their well-established roles in translation and splicing, members of noncoding RNA (ncRNA) families have recently been found to function in genome defense and chromosome inactivation. For example, piwi-interacting RNAs (piRNAs) prevent genome instability in germ line cells, while Xist (X-inactive-specific-transcript) is essential for X-chromosome inactivation in mammals.
Historically, American black bears occupied the majority of North America's forested regions. Today, they are primarily limited to sparsely settled, forested areas. American black bears currently inhabit much of their original Canadian range, though they seldom occur in the southern farmlands of Alberta, Saskatchewan and Manitoba; they have been extirpated on Prince Edward Island since 1937. Surveys taken in the mid-1990s found the Canadian black bear population to be between 396,000 and 476,000 in seven provinces; this estimate excludes populations in New Brunswick, the Northwest Territories, Nova Scotia and Saskatchewan. All provinces indicated stable populations of American black bears over the 2000s. The current range in the United States is constant throughout most of the Northeast and within the Appalachian Mountains almost continuously from Maine to northern Georgia, the northern Midwest, the Rocky Mountain region, the West Coast and Alaska. However, it becomes increasingly fragmented or absent in other regions. Despite this, American black bears in those areas seem to have expanded their range in recent decades, such as with sightings in Ohio, Illinois, southern Indiana, and western Nebraska. Sightings of itinerant black bears in the Driftless Area of southeastern Minnesota, northeastern Iowa, and southwestern Wisconsin are common.
Sources: en.wikipedia.org
In any case, general side effects of bicalutamide that might occur in either sex include diarrhea, constipation, abdominal pain, nausea, dry skin, itching, and rash. The drug is well-tolerated at higher dosages than 50 mg/day, up to 600 mg/day, with rare additional side effects. Bicalutamide has been associated with abnormal liver function tests such as elevated liver enzymes. In the Early Prostate Cancer (EPC) clinical programme of bicalutamide for LPC and LAPC, the rate of abnormal liver function tests with bicalutamide monotherapy was 3.4% relative to 1.9% for placebo. However, higher rates, up to 11%, have been seen in other studies. Hepatic changes that have necessitated discontinuation of bicalutamide, such as marked increases in liver enzymes or hepatitis, have occurred in 0.3–1.5% of men in clinical trials, or approximately 1% overall. Elevated liver enzymes with bicalutamide usually occur within the first 3 to 6 months of treatment. Monitoring of liver function during treatment is recommended, particularly in the first few months. In men with early prostate cancer, bicalutamide monotherapy has been found to increase non-prostate cancer mortality. The reasons for the increase in mortality with bicalutamide in these men are unknown, but possible factors could include androgen deprivation or drug-related toxicity of bicalutamide. There are 10 published case reports of liver toxicity associated with bicalutamide as of 2022. Death occurred in 2 of these cases.
==== PROSITE pattern notation ==== The PROSITE notation uses the IUPAC one-letter codes and conforms to the above description with the exception that a concatenation symbol, '-', is used between pattern elements, but it is often dropped between letters of the pattern alphabet. PROSITE allows the following pattern elements in addition to those described previously:
Other steps include the isolation of various security agencies to ensure that a synchronised attack could not succeed on all fronts and the planned appointment of a National Cyber Security Coordinator. As of that month, there had been no significant economic or physical damage to India related to cyber attacks. On 26 November 2010, a group calling itself the Indian Cyber Army hacked the websites belonging to the Pakistan Army and the others belong to different ministries, including the Ministry of Foreign Affairs, Ministry of Education, Ministry of Finance, Pakistan Computer Bureau, Council of Islamic Ideology, etc. The attack was done as a revenge for the Mumbai terrorist attacks. On 4 December 2010, a group calling itself the Pakistan Cyber Army hacked the website of India's top investigating agency, the Central Bureau of Investigation (CBI). The National Informatics Center (NIC) has begun an inquiry. In July 2016, Cymmetria researchers discovered and revealed the cyber attack dubbed 'Patchwork', which compromised an estimated 2500 corporate and government agencies using code stolen from GitHub and the dark web. Examples of weapons used are an exploit for the Sandworm vulnerability (CVE-2014–4114), a compiled AutoIt script, and UAC bypass code dubbed UACME. Targets are believed to be mainly military and political assignments around Southeast Asia and the South China Sea and the attackers are believed to be of Indian origin and gathering intelligence from influential parties.
Sources: en.wikipedia.org
Narrated by Fisher Dilke, produced by Nick Catliff, made by Lion Television 10 May A Sense of Disaster, about predicting earthquakes; Allan Lindh of the USGS; 17 October 1989 a large earthquake hit California, killing 67 people, with £7bn of damage in the 1989 Loma Prieta earthquake; Chen Li De of China; China predicted earthquakes by radon gas; Huang Xiang Ning, who predicted an earthquake near Tangshan in late July 1976 - the 1976 Tangshan earthquake occurred on 28 July 1976; the Great Hanshin earthquake on 17 January 1995 in Japan, the worst for seventy years in Japan; nuclear physicist Motoji Ikeya of the University of Osaka; geophysicist Joseph Kirschvink of Caltech, who had worked with bees and electromagnetic fields. Narrated by Barbara Flynn, produced by Bill Jones, directed by Chris Malone, made by Granada Television with the Discovery Channel 17 May Deadly Code, about biological weapons and genetic engineering; Vivienne Nathanson of the BMA; ethnic bioweapons; a religious cult leaves nerve gas on Tokyo underground trains in January 1995; Richard A.
Even though PMTX has no structural homology with other toxins acting on sodium channels, such as sea anemone toxins or scorpion toxins, some parts of these toxins show similar structures to interact with the receptor site of the sodium channels.
CPA is generally well-tolerated and has a mild side-effect profile regardless of dosage when it is used in combination with an estrogen in women. Side effects of CPA in general include hypogonadism (low sex-hormone levels) and associated symptoms such as demasculinization, sexual dysfunction, infertility, and osteoporosis (fragile bones); breast changes such as breast tenderness, breast enlargement, and gynecomastia (breasts in men); emotional changes such as fatigue and depression; and other side effects such as vitamin B12 deficiency, weak glucocorticoid effects, and elevated liver enzymes. Weight gain can occur with CPA when it is used at high doses. Some of the side effects of CPA can be improved or fully prevented if it is combined with an estrogen to prevent estrogen deficiency. Few quantitative data are available on many of the potential side effects of CPA. Pooled tolerability data for CPA is not available in the literature. Cyproterone is also known to suppress adrenocortical function. At very high doses in aged men with prostate cancer, CPA can cause cardiovascular side effects. Rarely, CPA can produce blood clots, liver toxicity (including hepatitis, liver failure, and liver cancer), excessively high prolactin levels, and certain benign brain tumors including meningiomas (tumors of the meninges) and prolactinomas (prolactin-secreting tumors of the pituitary gland). Upon discontinuation from high doses, CPA can produce adrenal insufficiency as a withdrawal effect.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.